Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00987337 · ClinicalTrials.gov registry record · Phase 2
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 288
- Enrollment target
NCT00987337 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 288 participants.
The verdict
NCT00987337, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 288 participants
- Enrollment target
Study Summary
The primary objective for this study is to determine if the addition of filibuvir to a standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the proportion of subjects who achieve a sustained viral response (SVR) compared to peginterferon/ribavirin (pegIFN/RBV) therapy alone.
Interventions
- DRUG Placebo
- DRUG Filibuvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00987337
The ClinicalTrials.gov registry entry for NCT00987337 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00987337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00987337 about?
NCT00987337 is a clinical study titled "Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects". The primary objective for this study is to determine if the addition of filibuvir to a standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the proportion of subjects who achieve a sustained viral response (SVR) compared to peginterferon/ribavirin (pegIFN/RBV) therapy alo...
What is the current status of trial NCT00987337?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 288 participants. The study started on 2009-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00987337?
The interventions under investigation include: Placebo (DRUG), Filibuvir (DRUG).
Who is sponsoring clinical trial NCT00987337?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.